U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2012
|
Price
|
| Publication Date: May 2012
Pages: 238
Publisher: iData Research
Table of Contents
The U.S. market for diabetes diagnosis, treatment and drug delivery is expected to exceed $17.87 billion by 2018.
The market segments covered in this report include:
• traditional blood glucose meters,
• continuous glucose monitoring systems,
• blood glucose test strips,
• lancets and lancing devices,
• insulin,
• insulin syringes,
• insulin pens and
• insulin pumps
Market growth is expected to be fueled by an increasing number of diabetics and improved education regarding the importance of blood glucose management. Factors such as high obesity rates, poor diet and lack of exercise will contribute to the growing type 2 diabetic population.
Market growth for diabetes diagnosis, treatment and drug delivery will be led by double-digit growth in the continuous glucose monitor, insulin pen and insulin pump segments.
Within the diabetes diagnosis, treatment and drug deliver market, companies such as Novo Nordisk, Sanofi, Eli Lilly and Lifescan lead the market, among many others. This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2018, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.
|
|
 |
|
|
|
|
Anti-Diabetic Pharmaceuticals Market in India 2012
Price: $795.00 (€626.57) ($954.00 (€751.89) Including VAT at 20%)
|
| Publication Date: Mar-2012
Pages: 76
Format: PDF
Publisher: Netscribes (India) Pvt. Ltd.
Sample Pages
Anti-diabetic pharmaceuticals market in India is one of the most lucrative diabetes markets in the world. Since India is the second largest diabetic pool in the world after China, the Indian market is characterized by a huge demand for anti-diabetic drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the number of diabetes cases, introduction of newer and better drugs, increasing aging population and introduction of diabetes insurance policies is helping the market to grow. The Indian Government, on its part, has introduced some diabetes control programmes. The market is expected to exhibit steady growth over the next few years.
The report begins with the introduction section which offers a brief classification of the different types of diabetes. It then gives a classification of the diabetes market, and then provides a brief description of different classes of anti-diabetic pharmaceuticals. The market overview section provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth. It also provides a global diabetes map.
An analysis of the drivers explains the factors for growth of the industry including increasing diabetes cases, introduction of newer and better drugs, increasing aging population and increase in health insurance policies. The key challenges include price regulation in the insulin market, competition from use of complementary and alternative medicines and maintainence of a healthy lifestyle to avoid diabetes.
The government initiatives section gives a brief description of the different diabetes programmes undertaken by the Government.
A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals for anti-diabetic drugs.
The competition section gives overview of pharmaceutical companies in the country operating in the anti diabetic pharmaceutical and insulin segments along with segmentation of players in respect to production of oral drugs and insulin. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario.
The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares.
Table of Contents |
|
|
|
|
|
|
|
|
|
|
Global Glucose Monitoring Market Report: 2012 Edition
Price: $800.00 (€630.51) ($960.00 (€756.62) Including VAT at 20%)
|
| Publication Date: Mar-2012
Format: PDF Email
Pages: 39
Publisher: Koncept Analytics
The worldwide market for blood glucose monitoring is mainly dependent on the number of diabetes patients in the world which is growing significantly and is expected to grow even further in the near future. As a result, the worldwide market for glucose monitoring devices should also grow. There is no cure for diabetes and it can only be controlled. In order to control it, blood glucose monitoring is mandatory.
Diabetes can be of 2 types i.e. type I and type II. Type II diabetes is so far more prevalent compared to type I. The type I diabetes can be monitored with the help of regular glucose monitoring devices and self monitoring blood glucose monitoring devices. Regular glucose monitoring is done with the help of standard hand prick glucose monitors. This segment contributes the major share of total sales of blood glucose monitoring industry. The blood glucose test strips which are required for glucose tests are disposable which means there is a steady growth opportunity in the glucose test strip market.
Continuous glucose monitoring is mainly required for type I diabetes patients or patients very high blood glucose level. A type I diabetes is less prevalent; the market for CGM (Continuous glucose monitoring) devices is smaller compared to Regular glucose monitoring market. CGM is a costlier procedure and is not covered automatically by medical insurances which also affect the sales of this particular segment. CGM is an invasive procedure and operation is required to place the sensor in the patient’s body. As soon as the reimbursement of CGM improves, the market should perform better.
The global aging population, obese population, worldwide health expenditure and awareness about diabetes are the factors which are fuelling the growth of the glucose monitoring industry. The unwillingness of patients in frequent glucose test and increased competition in the developed market are the major challenges to the growth.
The report provides an analysis of the glucose monitoring market. It also discusses the major trends, growth drivers and challenges in the market. The regular glucose monitoring market is mainly controlled by four major players namely Roche, J&J-Lifescan, Bayer and Abbott whereas the CGM market is controlled by Medtronic and Dexcom.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the global glucose monitoring devices market. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Contents/List of Tables/List of Figures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Diabetes Market Report: 2011 Edition
Price: $800.00 (€630.51) ($960.00 (€756.62) Including VAT at 20%)
|
| Publication Date: Oct-2011
Format: PDF Email
Pages: 58
Publisher: Koncept Analytics
Diabetes is a group of metabolic diseases in which a person has high blood sugar which is either due to the fact that insulin produced by the body is not enough or the body does not respond to the insulin that is produced in the body. Mainly there are three type of diabetes: Type 1 diabetes, Type 2 diabetes and gestational diabetes. Pre-diabetes is a condition that occurs when blood glucose level of a person is higher than normal but not high enough so as to diagnose for type 2 diabetes. Depending upon the speed at which the injected insulin is absorbed by the body, different types of insulin devices are available in the market. Diabetic population has been continuously increasing over the years. There are several factors responsible for increase in diabetic population like family history, obesity, smoking, alcohol, hypertension, etc.
Just the way human insulin replaced animal insulin, modern insulin is on the path of replacing human insulin. Ageing population and obesity are among the key drivers of diabetes market. Due to rising aging population, the probability of prevalence of chronic disease also increases which is a major cause of more and more people having diabetes. Urbanization leading to modern lifestyle also deeply influences the health of the people, thereby increasing the diabetic population.
Europe has the largest diabetic population and the largest insulin market followed by North America. Diabetes prevalence rate is high in the US and China. Novo Nordisk, Takeda, Sanofi-Aventis, Eli Lilly, Merck and GSK are among the largest players in diabetes market.
The report analyzes the global diabetes market including the US, Europe, Africa, South and Central America, South and Asia-Pacific. Key issues like lack of sufficient diagnosis and treatment facilities, cost and effective management have also been included in this report. The competition prevailing in the diabetes market has been analyzed with focus on global and regional market share of major players in diabetes and insulin market. The report also profiles the major players in the diabetes market.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the global diabetic population. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Table of Contents/List of Tables/List of Figures |
|
|
|
|
|
|
|
|
|
|
Epidemiology: Diabetes in China - Aging population, rising overweight and obesity are driving the diabetes epidemic
Price: $5,700.00 (€4,492.42) ($6,840.00 (€5,390.90) Including VAT at 20%)
|
| Publication Date: 16-Mar-2011
Please click here for more information or to purchase this report at our partner store
Diabetes mellitus is becoming an important chronic disease in countries experiencing rapid economic growth, especially China. In 2010, Datamonitor estimates that there were nearly 95 million people with diabetes mellitus in China. |
|
|
Epidemiology: Diabetes in India - a country faced with a mammoth diabetes epidemic
Price: $5,700.00 (€4,492.42) ($6,840.00 (€5,390.90) Including VAT at 20%)
|
| Publication Date: 16-Mar-2011
Please click here for more information or to purchase this report at our partner store
Diabetes mellitus is becoming an important chronic disease in countries experiencing rapid economic growth, especially India. In 2010, Datamonitor estimates that there were nearly 50 million people with diabetes mellitus. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epidemiology: Diabetes in China
Price: $5,700.00 (€4,492.42) ($6,840.00 (€5,390.90) Including VAT at 20%)
|
| Publication Date: 16-Mar-2011
Please click here for more information or to purchase this report at our partner store
Diabetes mellitus is becoming an important chronic disease in countries experiencing rapid economic growth, especially China. In 2010, Datamonitor estimates that there were nearly 95 million people with diabetes mellitus in China. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diabetes Market to 2016 - Biguanides and Insulin Analogs will be the Largest Selling Anti-Diabetic Drugs
|
Price
|
| Publication Date: 01-Dec-2010
Format: PDF
Pages: 153
Publisher:GBI Research
Sample Pages
GBI Research’s new report, “Diabetes Market to 2016 - Biguanides and Insulin Analogs to be the Largest Selling Anti-Diabetic Drugs”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global diabetes therapeutics market.. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
More... |
|
|
|
|
|
|
|
|
Antidiabetics market forecast
Price: $15,400.00 (€12,137.40) ($18,480.00 (€14,564.88) Including VAT at 20%)
|
| Publication Date: 17-Sep-2010
Please click here for more information or to purchase this report at our partner store
Analysis of the competitive landscape and the recent changes in antidiabetics across seven major markets. Analysis of the threats to currently marketed drugs. Assessment of the opportunities available to novel agent classes. |
|
|
Innovations in Diabetes Management with Food and Drinks
Price: $4,795.00 (€3,779.15) ($5,754.00 (€4,534.97) Including VAT at 20%)
|
| Publication Date: 08-Nov-2010
Please click here for more information or to purchase this report at our partner store
Diabetes affects over 285 million people around the world and this it forecast to increase to 438 million by 2030. Food, ingredient and drinks manufacturers are improving the content of food and beverages in response to the rising diabetes epidemic. |
|
|
Epidemiology: Type 2 Diabetes
Price: $5,700.00 (€4,492.42) ($6,840.00 (€5,390.90) Including VAT at 20%)
|
| Publication Date: 12-Dec-2010
Please click here for more information or to purchase this report at our partner store
Overview of type 2 diabetes definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations and a 10 year prevalent case forecast for type 2 diabetes and pre-diabetes across the seven major markets. |
|
|
Epidemiology: Type 1 Diabetes
Price: $5,700.00 (€4,492.42) ($6,840.00 (€5,390.90) Including VAT at 20%)
|
| Publication Date: 12-Dec-2010
Please click here for more information or to purchase this report at our partner store
Overview of type 1 diabetes definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year incident case forecast, and prevalent cases for 2010 across the seven major markets. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Be alerted by email of new featured reports
Browse upcoming events or submit your own